Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym
Go back to Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 119.02 +0.92 (0.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.10 | 52 Week High | $10.00 | |||
| Open | $119.37 | 52 Week Low | $3.22 | |||
| Day High | $121.11 | P/E | N/A | |||
| Day Low | $118.37 | EPS | $-0.46 | |||
| Volume | 859,681 | |||||
